https://pubmed.ncbi.nlm.nih.gov/38632314/
KRAS G12 mutations as adverse prognostic factors in KMT2A-rearranged acute myeloid leukemia
KRAS G12 mutations as adverse prognostic factors in KMT2A-rearranged acute myeloid leukemia
https://pubchem.ncbi.nlm.nih.gov/gene/kmt2a/zebrafish
kmt2a (zebrafish) | Gene Target - PubChem
Gene target information for kmt2a - lysine (K)-specific methyltransferase 2A (zebrafish). Find diseases associated with this biological target and compounds...
zebrafishgenetargetpubchem
https://research-repository.uwa.edu.au/en/publications/preclinical-assessment-of-dactinomycin-in-kmt2a-rearranged-infant/
Preclinical Assessment of Dactinomycin in KMT2A-Rearranged Infant Acute Lymphoblastic Leukemia -...
preclinicalassessment
https://severus.dbmi.pitt.edu/wiki-MPM/index.php/pair/view/6045/4297
RNF2 and KMT2A - Wiki-MPM
Wiki-wiki: a wiki resource centered on human protein-protein interactions
wikimpm
https://pubmed.ncbi.nlm.nih.gov/40646135/
Ontogeny-specific induction of the KMT2A::AFF1-fusion drives development of a distinct CD24...
Infant Acute Lymphoblastic Leukemia (ALL) driven by the KMT2A::AFF1 onco-fusion is an aggressive, poor prognosis disease with few co-operative mutations. The...
https://www.cancer.gov/research/participate/clinical-trials-search/v?id=NCI-2026-00501
Revumenib and Mezigdomide for the Treatment of Relapsed or Refractory KMT2A-Rearranged,...
Revumenib and Mezigdomide for the Treatment of Relapsed or Refractory KMT2A-Rearranged, NPM1-Mutant, and NUP98-Rearranged Acute Leukemias
for the
https://www.cancer.gov/research/participate/clinical-trials-search/v?id=NCI-2019-07963
A Study of Revumenib in R/R Leukemias Including Those With an MLL/KMT2A Gene Rearrangement or NPM1...
A Study of Revumenib in R/R Leukemias Including Those With an MLL/KMT2A Gene Rearrangement or NPM1 Mutation
https://mau.diva-portal.org/smash/record.jsf?pid=diva2:1971072
The role of cell surface CD24 and interferons in KMT2A::AFF1 paediatric leukaemia
https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-revumenib-relapsed-or-refractory-acute-leukemia-kmt2a-translocation
FDA approves revumenib for relapsed or refractory acute leukemia with a KMT2A translocation | FDA
On November 15, 2024, the Food and Drug Administration approved revumenib (Revuforj, Syndax Pharmaceuticals, Inc.), a menin inhibitor, for relapsed or...